Appraisal 189

NICE Single Technology Appraisal Guidance No 189

Sorafenib for the treatment of advanced hepatocellular carcinoma

This NICE guidance was published on 26 May 2010. The web reference for the appraisal and other related documents is:

NHSScotland should note that:

1. Recommendations of NICE Single Technology Appraisals (STAs) have no status in NHSScotland.

2. NHS boards should adhere to the Scottish Medicines Consortium (SMC) advice.

SMC published a Statement of Advice (482/08) on this medication for this indication in January 2011. This stated:

Sorafenib (Nexavar®) is not recommended for use within NHSScotland for the treatment of hepatocellular carcinoma.

Access the advice of SMC

3. There is no material difference between the recommendations of the NICE STA and SMC.

Published Date: 26 May 2010


Reviewed for Scotland

This advice has been reviewed under our procedure for processing NICE appraisals to ensure it is relevant for the Scottish healthcare landscape.

Read our process for reviewing NICE guidance